The FDA proposes new rules allowing mutation-specific gene therapies to qualify for approval despite extremely small patient ...

Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.

Introduced for the 1964 model year as a competitor for the downsized Ford Fairlane, the Chevrolet Chevelle quickly morphed into a fully-fledged muscle car. High-performance highlights include the Z-16 ...

It is well known within the biopharma industry that clinical studies can produce any number of unexpected and possibly disappointing outcomes, including false negative results, or in statistical ...